Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 1, 2016, Pages 124-131.e1

  Mittal, Sahil ^a,b   El Serag, Hashem B ^a,b   Sada, Yvonne H ^a,b   Kanwal, Fasiha ^a,b   Duan, Zhigang ^a   Temple, Sarah ^a   May, Sarah B ^a   Kramer, Jennifer R ^a   Richardson, Peter A ^a   Davila, Jessica A ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Fatty liver; Liver cancer; NASH; Steatosis

Indexed keywords

ADULT; AGE; AGED; ALCOHOL ABUSE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; UNITED STATES; VETERAN; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; UNITED STATES; VETERANS;

EID: 84958966834     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.07.019     Document Type: Article

References (31)

1. Mittal S., El-Serag H.B. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013, 47(Suppl):S2-S6.
2. Wong G.L., Chan H.L., Chan H.Y., et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013, 144:933-944.
3. Stroffolini T., Andreone P., Andriulli A., et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998, 29:944-952.
4. Albeldawi M., Soliman M., Lopez R., et al. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients. Dig Dis Sci 2012, 57:3265-3270.
5. Bralet M.P., Regimbeau J.M., Pineau P., et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000, 32:200-204.
6. Grazi G.L., Cescon M., Ravaioli M., et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics: evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 2003, 17(Suppl 2):119-129.
7. Guzman G., Brunt E.M., Petrovic L.M., et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008, 132:1761-1766.
8. Lerut J., Mergental H., Kahn D., et al. Place of liver transplantation in the treatment of hepatocellular carcinoma in the normal liver. Liver Transpl 2011, 17(Suppl 2):S90-S97.
9. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
10. Smoot R.L., Nagorney D.M., Chandan V.S., et al. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg 2011, 98:697-703.
11. Yeh M.M., Daniel H.D., Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol 2010, 23:276-283.
12. Ertle J., Dechene A., Sowa J.P., et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011, 128:2436-2443.
13. VA information resource center. Available at: Accessed April 24, 2014. http://www.virec.reserach.va.gov/VSF/overview.htm.
14. Davila J.A., Weston A., Smalley W., et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007, 41:777-782.
15. Bruix J., Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
16. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
17. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
18. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010, 53:348-356.
19. Fattovich G., Olivari N., Pasino M., et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57:84-90.
20. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
21. Trevisani F., Frigerio M., Santi V., et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010, 42:341-347.
22. Yasui K., Hashimoto E., Komorizono Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:428-433.
23. Reddy S.K., Steel J.L., Chen H.W., et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012, 55:1809-1819.
24. Sanyal A., Poklepovic A., Moyneur E., et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010, 26:2183-2191.
25. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
26. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
27. Lin Z.H., Xin Y.N., Dong Q.J., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011, 53:726-736.
28. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
29. Lai S.W., Chen P.C., Liao K.F., et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012, 107:46-52.
30. Hassan M.M., Curley S.A., Li D., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116:1938-1946.
31. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.